Dr. Elise Olsen and associates (Olsen et al., 1997) discovered that reducing the frequency of tretinoin 0.05% cream from once daily to 3 times per week maintains, and in some cases, possibly ...

12 weeks as opposed to the daily treatment with 0.1% tretinoin cream, which required 24 weeks to achieve the same outcomes. 38, 39 In comparison with 70% glycolic acid peel, the 1% tretinoin peel was ...

Pakistan’s headline inflation dropped to 0.3% year-on-year in April 2025, down from 0.7% in March, according to Pakistan Bureau of Statistics (PBS) data released Friday. On a month-on-month ...

Some prescription creams use tretinoin as one of their main ingredients. For example, Renova is a cream that contains 0.2% tretinoin. It’s FDA-approved to reduce facial wrinkles, but only when used as ...

ideally with a cream base. A lower potency and a more nourishing base will help your skin adjust to the tretinoin and minimize the common side effects of irritation, dryness, redness, and peeling.

All products featured on Vogue are independently selected by our editors. However, we may receive compensation from retailers and/or from purchases of products through these links. They always say ...

The approval of ZORYVE cream 0.15% for atopic dermatitis in Canada was supported by positive results from the vehicle-controlled pivotal Phase 3 INTEGUMENT-1 and INTEGUMENT-2 trials, in which ...

U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of October 13, 2025 Application supported by positive efficacy and safety data from ...

On February 26, 2025, roflumilast cream 0.05% (Zoryve; Arcutis Biotherapeutics) took a step forward on the FDA pipeline, as the federal agency has accepted the topical cream's supplemental new drug ...

The data showed significant improvements as early as Week 1. At Week 4, 25.4% of children treated with ZORYVE cream 0.05% achieved vIGA-AD Success, defined as a validated Investigator Global ...

Roflumilast cream 0.05% was well-tolerated. Overall, the safety profile observed in 2‑ to 5‑year‑old pediatric subjects treated with ZORYVE cream 0.05% during the trial was consistent with the ...